BR112015028613A2 - análogos de uréia com ligações por pontes substituída como moduladores de sirtuína - Google Patents

análogos de uréia com ligações por pontes substituída como moduladores de sirtuína

Info

Publication number
BR112015028613A2
BR112015028613A2 BR112015028613A BR112015028613A BR112015028613A2 BR 112015028613 A2 BR112015028613 A2 BR 112015028613A2 BR 112015028613 A BR112015028613 A BR 112015028613A BR 112015028613 A BR112015028613 A BR 112015028613A BR 112015028613 A2 BR112015028613 A2 BR 112015028613A2
Authority
BR
Brazil
Prior art keywords
disorders
diseases
sirtuin
substituted bridged
proposed
Prior art date
Application number
BR112015028613A
Other languages
English (en)
Inventor
H White Brian
G Szczepankiewicz Bruce
A Blum Charles
Oalmann Christopher
S Disch Jeremy
Koppetsch Karsten
Yee Ng Pui
Casaubon Rebecca
Dana Caldwell Richard
B Perni Robert
Michael Fox Ryan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015028613A2 publication Critical patent/BR112015028613A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “análogos de uréia com ligações por pontes substituída como moduladores de sirtuína” são propostos no presente documento uréia com ligações por pontes substituída e análogos relacionados inovadores e métodos inovadores do seu uso. os compostos moduladores de sirtuína podem ser usados para prolongar a vida de uma célula, e para o tratamento e/ou a prevenção de uma ampla variedade de doenças e distúrbios incluindo, por exemplo, doenças ou distúrbios relacionados com o envelhecimento ou o estresse, diabetes, obesidade, doenças neurodegenerativas, doença cardiovascular, distúrbios de coagulação sanguínea, inflamação, câncer e/ou rubor assim como doenças ou distúrbios que se beneficiariam de uma atividade mitocondrial aumentada. além disso, são propostas composições compreendendo um composto modulador de sirtuína em combinação com um outro agente terapêutico.
BR112015028613A 2013-05-13 2014-05-13 análogos de uréia com ligações por pontes substituída como moduladores de sirtuína BR112015028613A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361822758P 2013-05-13 2013-05-13
PCT/US2014/037767 WO2014186313A1 (en) 2013-05-13 2014-05-13 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
BR112015028613A2 true BR112015028613A2 (pt) 2017-07-25

Family

ID=53264426

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015028613A BR112015028613A2 (pt) 2013-05-13 2014-05-13 análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
BR112017010592A BR112017010592A2 (pt) 2013-05-13 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017010592A BR112017010592A2 (pt) 2013-05-13 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Country Status (11)

Country Link
US (4) US9765075B2 (pt)
EP (2) EP2997029B1 (pt)
JP (2) JP6376707B2 (pt)
KR (2) KR20160006215A (pt)
CN (2) CN105392788B (pt)
AU (3) AU2014265671B2 (pt)
BR (2) BR112015028613A2 (pt)
CA (2) CA2912683A1 (pt)
ES (1) ES2718550T3 (pt)
RU (2) RU2015153061A (pt)
WO (1) WO2014186313A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6272833B2 (ja) * 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
WO2014186313A1 (en) 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
JP2016079173A (ja) * 2014-10-15 2016-05-16 日本合成化学工業株式会社 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物
WO2016079709A1 (en) * 2014-11-19 2016-05-26 Glaxosmithkline Intellectual Property (No.2) Limited Substituted bridged urea analogs as sirtuin modulators
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019040404A1 (en) * 2017-08-21 2019-02-28 Microbiotix, Inc. METABOLIC-STABLE METABOLIC-N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
JP7156207B2 (ja) * 2019-08-07 2022-10-19 株式会社島津製作所 糖ペプチド解析装置
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用
CN112645805A (zh) * 2020-12-23 2021-04-13 北京理工大学 一种由温勒伯酰胺制备均苯三甲醛的方法
CN115518062B (zh) * 2022-09-02 2024-03-22 成都大学 Phellopterin在制备用于治疗STAT信号通路介导的相关疾病药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE4424484A1 (de) * 1994-07-12 1996-01-18 Bayer Ag Azofarbstoffe, deren Herstellung und Verwendung
KR20070033032A (ko) * 2004-07-16 2007-03-23 프로테오시스 악티엔게젤샤프트 세포보호제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을 갖는무스카린 길항제
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
JP5506386B2 (ja) * 2006-09-04 2014-05-28 ユニバーシティー・コート・オブ・ザ・ユニバーシティー・オブ・ダンディー Ｐ５３活性化化合物
AU2008339572B2 (en) * 2007-12-21 2012-05-10 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
MX2010012010A (es) 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quinolinas y analogos relacionados como moduladores de sirtuin.
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
WO2010056549A1 (en) * 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
UA104447C2 (uk) 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Тіазолопіридинові сполуки, що модулюють сиртуїн
US9556201B2 (en) * 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
WO2013059594A1 (en) 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2014186313A1 (en) 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
WO2016081692A2 (en) 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
KR20170084274A (ko) 2017-07-19
BR112017010592A2 (pt) 2018-03-06
EP3221312A2 (en) 2017-09-27
JP6376707B2 (ja) 2018-08-22
JP2017536364A (ja) 2017-12-07
AU2014265671B2 (en) 2017-04-06
AU2014265671A1 (en) 2015-11-26
AU2015349912A1 (en) 2017-06-01
KR20160006215A (ko) 2016-01-18
CN107207496A (zh) 2017-09-26
ES2718550T3 (es) 2019-07-02
CA2975291A1 (en) 2016-05-26
EP2997029A1 (en) 2016-03-23
JP6833686B2 (ja) 2021-02-24
US20150152108A1 (en) 2015-06-04
US20180044338A1 (en) 2018-02-15
US20160083386A1 (en) 2016-03-24
WO2014186313A1 (en) 2014-11-20
CN105392788A (zh) 2016-03-09
EP3221312A4 (en) 2018-05-30
AU2017204176B2 (en) 2018-07-26
US9765075B2 (en) 2017-09-19
AU2014265671A8 (en) 2016-06-16
US10590135B2 (en) 2020-03-17
EP2997029B1 (en) 2019-01-09
US9834558B2 (en) 2017-12-05
CN105392788B (zh) 2018-10-23
RU2017120859A (ru) 2018-12-20
RU2015153061A (ru) 2017-06-15
JP2016518448A (ja) 2016-06-23
US20170355697A1 (en) 2017-12-14
WO2014186313A8 (en) 2015-12-23
EP2997029A4 (en) 2017-05-24
AU2017204176A1 (en) 2017-07-13
RU2015153061A3 (pt) 2018-03-21
CA2912683A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
BR112015028613A2 (pt) análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
BR112012010010A2 (pt) piridinas bicíclicas e análogos como moduladores da sirtuína
CR20110353A (es) Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada
UY31170A1 (es) Compuestos moduladores de sirtuina
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
DOP2009000284A (es) Compuestos de tiazolopiridina moduladores de sirtuina
EP2342188A4 (en) CHROMENONE ANALOGUES AS MODULATORS OF SIRTUIN
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112017010601A2 (pt) análogos de ureia substituídos em ponte como moduladores de sirtuínas
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
EA201170137A1 (ru) Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CR20110509A (es) Composicion farmaceutica
EA201071263A1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
BR112014003704A2 (pt) moduladores ror gama
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112015019412A2 (pt) inibidores de bace1
BR112015019919A2 (pt) compostos bicíclicos
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 471/04

Ipc: C07D 471/04 (2006.01), A61P 17/10 (2006.01)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]